To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Jack Ma’s Yunfeng in HK-listed pharma deal
A consortium including the private equity firm has subscribed to $1.6bn worth of Baiyunshan shares
